HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED
Get an alert when HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£2.1M
USD 2,845,000
+422% vs 2023
Net assets
-£1.8M
USD -2,359,000
-13,005.6% vs 2023
Employees
—
Average over period
Profit before tax
-£1.8M
USD -2,359,000
-233.2% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Negative shareholders' funds
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | — | £5,620,602 | — | |
| Operating profit | -£530,768 | -£1,679,144 | -216.4% | |
| Profit before tax | -£530,019 | -£1,765,983 | -233.2% | |
| Net profit | -£530,019 | -£1,765,983 | -233.2% | |
| Cash | £407,995 | £2,129,810 | +422% | |
| Total assets less current liabilities | -£13,475 | £4,297,799 | +31,994.6% | |
| Net assets | -£13,475 | -£1,765,983 | -13,005.6% | |
| Equity | -£13,475 | -£1,765,983 | -13,005.6% | |
| Average employees | — | — | — | |
| Wages | £369,067 | £952,987 | +158.2% | |
| Directors' remuneration | £0 | £0 | — |
Figures converted to GBP from USD at 0.749 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | — | -29.9% | |
| Net margin | — | -31.4% | |
| Return on capital employed | — | -39.1% | |
| Current ratio | 0.97x | 1.00x | |
| Interest cover | — | -11.50x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED 2018-10-19 → present
- WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED 2011-09-14 → 2018-10-19
- WEST-WARD (GB) LIMITED 2011-06-23 → 2011-09-14
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company has net liabilities at 31 December 2024 of $2,359k (2023: net liabilities $18k). The Company has a letter of support in place from its ultimate parent company, Hikma, which states that, should it be required, Hikma will provide financial support to the Company for additional funding or to enable it to discharge its liabilities as they fall due for the foreseeable future. The Directors have assessed the ability of Hikma to provide that support and, on that basis, have concluded that the application of the going concern basis of preparation of the financial statements is appropriate.”
Group structure
- HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED · parent
- Hikma d.o.o. 100%
- Hikma Services India Private Limited 1%
Significant events
- “During the year, the Company opened Hikma Pharmaceuticals International Limited, London, Geneva Branch (the "Swiss Branch") to supervise the global manufacturing and distribution of certain pharmaceutical products...”
- “In September 2024, the Company acquired a new subsidiary, an R&D center located in Zagreb, Croatia, as part of the Group's acquisition of the Xellia business.”
- “While the Company became a holding company during the year, its primary activities continue to relate to the wholesale distribution of medicinal products in the United Kingdom.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 21 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MIDDLEMIST, Helen | Secretary | 2022-07-18 | — | — |
| AL KURDI, Areb | Director | 2022-08-15 | Oct 1974 | Jordanian |
| VERISSIMO, Goncalo Pina Pereira | Director | 2025-03-25 | Nov 1977 | Portuguese |
Show 21 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| SPEIRS, Peter Alexander | Secretary | 2011-06-23 | 2022-06-15 |
| ABDEL-HAFEZ, Maen Abdel-Hamid Abdullah | Director | 2011-07-04 | 2014-11-04 |
| ARKHAQA, Hussein | Director | 2011-06-23 | 2014-11-04 |
| ASFEHA, Abrehet | Director | 2011-10-17 | 2014-11-04 |
| ATWAL, Gurpal Singh | Director | 2019-09-02 | 2022-02-11 |
| ATWAL, Gurpal Singh | Director | 2011-07-04 | 2016-09-07 |
| AWAD, Basel Ibrahim Bakir, Dr | Director | 2017-01-17 | 2019-09-02 |
| CREASE, Thomas Michael | Director | 2014-11-04 | 2015-01-05 |
| DARWAZAH, Tareq Mazen Samih | Director | 2011-07-04 | 2014-11-04 |
| HANSEN, Joanna Elizabeth | Director | 2020-03-30 | 2025-03-25 |
| HOFFMANN, Brian Scott | Director | 2016-08-25 | 2018-04-16 |
| HYDE, Jane Celia | Director | 2016-04-12 | 2016-09-07 |
| KHOURI, Bana | Director | 2022-04-01 | 2025-03-25 |
| MASARWEH, Natheer | Director | 2017-01-17 | 2019-09-02 |
| MIDDLEMIST, Helen | Director | 2022-07-18 | 2025-03-25 |
| MISHLAWI, Riad | Director | 2016-06-15 | 2019-09-02 |
| RAHMANI, Nassim | Director | 2022-12-07 | 2025-03-25 |
| RAYA, Michael Alex | Director | 2016-10-07 | 2017-12-31 |
| SAVASTANO, Frank Louis | Director | 2016-09-09 | 2019-09-02 |
| SPEIRS, Peter Alexander | Director | 2018-04-16 | 2022-06-15 |
| SPEIRS, Peter Alexander | Director | 2014-11-04 | 2016-09-07 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | Corporate entity | Shares 75–100% | 2016-06-25 | Ceased 2017-06-28 |
| Hikma Uk Limited | Corporate entity | Shares 75–100% | 2016-05-25 | Active |
Filing timeline
Last 20 of 100 total filings
Material constitutional events — rename, articles re-file, resolution
- 2022-09-29 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-10-04 | AA | accounts | Accounts with accounts type full | |
| 2025-09-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-03-26 | AP01 | officers | Appoint person director company with name date | |
| 2025-03-26 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-26 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-26 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-26 | TM01 | officers | Termination director company with name termination date | |
| 2024-09-03 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-09-02 | CH01 | officers | Change person director company with change date | |
| 2024-07-26 | AA | accounts | Accounts with accounts type full | |
| 2023-11-24 | AA | accounts | Accounts with accounts type full | |
| 2023-09-08 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-12-08 | AP01 | officers | Appoint person director company with name date | |
| 2022-10-01 | AA | accounts | Accounts with accounts type full | |
| 2022-09-29 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2022-09-29 | SH20 | capital | Legacy | |
| 2022-09-29 | CAP-SS | insolvency | Legacy | |
| 2022-09-29 | RESOLUTIONS | resolution | Resolution | |
| 2022-09-28 | SH01 | capital | Capital allotment shares | |
| 2022-09-13 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.